Elaine Allison, CSP
Co-founder & CEO
Ms. Allison has over 25 years of experience in leadership roles, management consulting globally, and fund raising. She has been a serial entrepreneur since 1999 starting and managing several successful ventures. She implements effective business strategy utilizing a lean business model. Ms. Allison is also skilled at project management, risk management and raising capital. She is the author of a bestselling leadership book entitled, “The Velvet Hammer – PowHERful Leaderships Lessons for Women Who Don’t Golf”. Ms. Allison previously served in the role of Vice President of Business Development at Novelogics. She has been instrumental in creating the company, and setting the direction for all phases of growth.
Dr. Wayne Cheney, PhD
Co-founder, President and Chief Scientific Officer
Dr. Cheney has over 28 years of combined R&D experience with 18 years in the biopharmaceutical industry and another 10 years performing research in academic and government labs in both Canada and the U.S. Significantly, 12 years of his R&D experience have focused directly on oncology. Dr. Cheney was principal scientist and project leader for several successful discovery/pre-clinical development phase compounds for epilepsy, as well as for gout and cancer, while at Valeant Pharmaceuticals and Ardea Biosciences, respectively, and significantly helped translate these compounds into the clinic. Specifically, Potiga®/Trobalt® (Valeant/GSK) is now a marketed drug in the U.S. and EU for treatment of epileptic partial on-set seizures, while Ardea Biosciences’ (now Astra Zeneca) gout drug Zurampic® is marketed in the U.S. (now by Ironwood), and EU, and their oncology drug BAY 86-9766 reached phase II clinical testing with partner Bayer Healthcare AG.
Dr. Cheney received his PhD in Molecular Biology from the University of Wyoming (U.S.), a BSc in Biology from the University of Waterloo (Canada) and has performed post-doctoral research at Temple University (Fels Institute for Cancer Research) in Philadelphia, and at Canji, Inc. (a Schering-Plough subsidiary, now Merck) in San Diego. He has published a number of peer-reviewed scientific publications and has been named as co-inventor or inventor on four patents, and has others pending.
Scientific & Management Advisory
Dr. Randall Moreadith, MD, PhD
President and Chief Executive Officer, Serina Therapeutics, Inc. , AL, USA
SVP, Chief Development Officer, Nektar Therapeutics
Chief Medical Officer, Renovis , Inc.
Wayne Cockburn (Advisor)
Managing Director, International Capital Management, Inc.
Some of our Partners & Contract Research Labs